BiotechTube

BIIB112

Phase 1/2Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

X-Linked Retinitis Pigmentosa

Conditions

X-Linked Retinitis Pigmentosa

Trial Timeline

Mar 8, 2017 → Nov 18, 2020

NCT ID
NCT03116113

About BIIB112

BIIB112 is a phase 1/2 stage product being developed by Biogen for X-Linked Retinitis Pigmentosa. The current trial status is completed. This product is registered under clinical trial identifier NCT03116113. Target conditions include X-Linked Retinitis Pigmentosa.

What happened to similar drugs?

2 of 8 similar drugs in X-Linked Retinitis Pigmentosa were approved

Approved (2) Terminated (0) Active (6)
🔄KRN23Kyowa KirinPhase 3
🔄burosumab + Oral Phosphate Supplement + active vitamin DKyowa KirinPhase 3
🔄burosumabKyowa KirinPhase 3
✅KRN23Kyowa KirinApproved
🔄BurosumabKyowa KirinPhase 3
🔄BurosumabKyowa KirinPhase 3
🔄burosumabKyowa KirinPhase 3

Hype Score Breakdown

Clinical
9
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03116113Phase 1/2Completed

Competing Products

20 competing products in X-Linked Retinitis Pigmentosa

See all competitors
ProductCompanyStageHype Score
VK0214Viking TherapeuticsPhase 1
26
Methylprednisolone + Prednisolone + SirolimusAstellas PharmaPhase 1/2
39
BurosumabKyowa KirinPhase 1/2
32
BurosumabKyowa KirinPre-clinical
30
BurosumabKyowa KirinPre-clinical
26
BurosumabKyowa KirinPhase 2
35
KRN23Kyowa KirinPhase 1/2
32
KRN23Kyowa KirinPhase 3
40
burosumab + Oral Phosphate Supplement + active vitamin DKyowa KirinPhase 3
40
burosumabKyowa KirinPhase 3
40
KRN23Kyowa KirinApproved
43
burosumabKyowa KirinPhase 2
35
BurosumabKyowa KirinPhase 3
40
KRN23Kyowa KirinPhase 1/2
32
Placebo + KRN23Kyowa KirinPhase 1
29
BurosumabKyowa KirinPhase 3
40
burosumabKyowa KirinPhase 3
40
KRN23Kyowa KirinPhase 2
35
KRN23Kyowa KirinPhase 1
29
KRN23Kyowa KirinApproved
43